ClinicalTrials.gg
RecruitingNCT07107022i-RISEUpdated Oct 20, 2026

Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

An observational study in Acute Ischemic Stroke (AIS), sponsored by Penumbra Inc.. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Penumbra Inc. · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 20, 2026First site in CanadaStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Ischemic Stroke by Penumbra Inc. — 2 open to participants now, 2 under way, none of them phase 3. Ischemic Stroke · Penumbra Inc..

Started
2025
the only one that year
Observational
9 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Ischemic Stroke by Penumbra Inc., this one is the only one that started in 2025, is one of 9 observational ones, and was the 13th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

2 of the 14 studies in Ischemic Stroke by Penumbra Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ischemic Stroke by Penumbra Inc., or all of them as a file.
02

Study summary

The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)

Read the detailed description

Post-market, real-world, prospective, single-arm, multi-center study that will enroll up to 200 participants at up to 15 sites globally

03

Conditions studied

  • Acute Ischemic Stroke (AIS)

Browse trials for

Keywords

  • Penumbra System
  • Thrombectomy
  • Penumbra ENGINE®
  • mechanical thrombectomy
  • Neuro Thrombectomy
  • Neurovascular Catheters
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting with acute ischemic stroke (AIS) who are eligible for aspiration based mechanical thrombectomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I.1. Patient age 18-80 years
  • I.2. Pre-stroke mRS 0-1
  • I.3. Patients experiencing acute ischemic stroke who are eligible for mechanical thrombectomy using the Penumbra System
  • I.4. Frontline treatment with Penumbra System
  • I.5. Signed per Institution Review Board/Ethics Committee

Exclusion criteria

Exclusion Criteria:

  • E.1. Alberta Stroke Program Early CT Score (ASPECTS) ≤6 (for anterior circulation strokes)
  • E.2. Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days
  • E.3. Currently participating in an (drug, device, etc.) clinical trial that will influence the endovascular procedure or acute treatment of the patient. Patients in secondary prevention, observational, natural history, and/or
  • epidemiological studies are eligible.
  • E.4. Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with acute ischemic stroke (AIS)

    Device: Penumbra System®

    Device: Penumbra System ®

Interventions

  • DevicePenumbra System ®

    Neurovacular Mechanical Thrombectomy with the Penumbra System®

06

What researchers measure

Primary outcomes

  1. Outcomes:

    Angiographic revascularization of the occluded target vessel immediately post- procedure as defined by modified Thrombolysis in Cerebral Infarction (mTICI) 2b or higher Angiographic revascularization of the occluded target vessel immediately post- procedure as defined by mTICI 2c or higher * Angiographic revascularization of the occluded target vessel after the first pass as defined by mTICI 2b or higher * Angiographic revascularization of the occluded target vessel after the first pass as defined by mTICI 2c or higher

    Time frame: It is anticipated this study will take approximately 2 years. All participants will be followed for approximately 90-day or to outcome (e.g., withdrawal, death), whichever occurs first.

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 26 months is close to that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 6, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Canada
Show 2 added (2 Canada)
  • Kelowna General Hospital · Kelowna, Canada
  • Toronto Western Hospital · Toronto, Canada
Oct 20, 2026
Contact
Study contact changed: e•••@penumbrainc.com · •••2028→m•••@penumbrainc.com · •••6232. See the current contact
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites added — first site in Canada
    Show 2 added (2 Canada)
    • Kelowna General Hospital · Kelowna, Canada
    • Toronto Western Hospital · Toronto, Canada
    Contact Study contact changed: e•••@penumbrainc.com · •••2028→m•••@penumbrainc.com · •••6232. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07107022
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Nov 1, 2025
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Celina Wang
Contact
cwang1@penumbrainc.com
+49 175 1938 209
Marie-Pierre Dewez
Contact
mpdewez@penumbrainc.com
+32 499036232
Marios Nikos Psychogios, Prof MD
principal investigator · University Hospital of Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion